RIPK3 and cancer: The loss of key necroptotic proteins in cancers has become a major hindrance for necroptosis-based therapy [73, 74] but results of our recent studies in CCA patients demonstrated that RIPK3 and MLKL were both expressed in a great majority of CCA patients, allowing for the possible development of necroptosis-based therapeutic approaches [75].